Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews current evaluation and treatment options for androgenic alopecia in women and reports no new clinical results.

This review discusses idiopathic hirsutism and suggests that combination treatment, including androgen suppression and cosmetic methods, is most effective, but notes that its pathogenesis remains unclear.

In this study, distinct androgen excess subtypes were identified in women with PCOS, with the adrenal androgen excess cluster showing significantly higher rates of insulin resistance and type 2 diabetes, suggesting 11-oxygenated androgens as potential drivers of metabolic risk.

In this study, treating prolactinoma with cabergoline normalized prolactin levels and affected some androgen-related parameters, but did not significantly improve hirsutism in affected women.

This systematic review reported positive outcomes with gender-affirming hormone therapy in Canada and emphasized the urgent need for standardized outcome measurement tools to enhance evidence-based practices.

This article presents a case of congenital adrenal hyperplasia and myelolipoma in a 56-year-old woman, describing her symptoms and characteristics without offering new clinical results.

This report describes varied causes of hirsutism in young females and highlights the need to revise diagnoses if initial treatments for common etiologies like PCOS do not yield results.

This research reviewed existing literature to explore treatment options for androgen-dependent diseases, reporting that among prostate cancer therapies analyzed, the drug olaparib as monotherapy resulted in longer survival compared to the combination of apalutamide and abiraterone, though combined treatment efficacy differences were not statistically significant.

This study found that hirsutism patients had a strong correlation with polycystic ovary syndrome and elevated levels of certain hormones, such as 17-OHP and serum testosterone.

This review discusses evidence on androgen sensitivity as a potential factor in COVID-19 disease severity, suggesting that androgen receptor interactions could influence virus entry and progression, and reports no new clinical results.

This study found that BMI was the only significant predictor of elevated androgen levels in adolescents with PCOS, and hyperandrogenemia was not linked to a specific PCOS phenotype.

This paper discusses the proposal that androgenetic alopecia, as seen in the "Gabrin sign", could indicate higher risk of severe COVID-19 symptoms, but its validity is questioned and further confirmation is needed.

This review discusses the role of CYP gene polymorphisms in exacerbating hyperandrogenism in women with PCOS and reports no clinical results; further validation of this hypothesis is needed.

In this review, researchers examined the complex interaction of hormones, genes, and reactive oxygen species in hirsutism and PCOS, highlighting prolactin's role in modulating hormone levels linked to hair growth disorders.

This review discusses the prevalence and clinical impact of menstrual abnormalities, acne, and hirsutism in young women with Cushing's syndrome and reports no new clinical results.

This study suggests that dihydrotestosterone plays a key role in the development of chronic allograft nephropathy, and inhibiting androgens may improve long-term kidney transplant outcomes.

In this study, the researchers observed that antiandrogen treatment with Cyproterone acetate led to atrophy of pilo-sebaceous units and may activate Langerhans cells, contributing to local inflammation.

This review examines the effects of antiandrogens on female reproductive systems, particularly regarding environmental endocrine disruptors, and presents no new research findings.

In this narrative review, the authors discuss the potential impact of hormone therapy on androgenetic alopecia among transgender individuals, especially transgender men using testosterone, and its adverse effects on emotional well-being and body image within a socially stigmatized population.

This study describes a family with X-linked gynecomastia and undervirilization in men, finding a subtle androgen receptor abnormality that may not always lead to infertility despite androgen resistance.

This study found that targeting the p300/androgen receptor axis effectively reduced AR activation and ovarian fibrosis in mouse models of polycystic ovary syndrome, suggesting a potential therapeutic approach.

This article reviews the metabolism and action of androgen in the skin but reports no new experimental results; the author calls for further research.

This case report describes a 64-year-old woman with male pattern hair loss and elevated testosterone levels, who was diagnosed with an androgen-secreting adrenal tumor and successfully treated with laparoscopic adrenalectomy.

This study concludes that high skin 5α-reductase activity may contribute to hirsutism, but the specific regulatory mechanisms and genetic factors remain unclear.

This review discusses the etiology and clinical findings of atypical hyperadrenocorticism in dogs due to sex steroid imbalance and explores various treatment options, but reports no new results.

This review discusses the definition, causes, diagnostic strategies, and treatment options for hirsutism in women without reporting new clinical results, and highlights the impact of the condition on self-esteem.

This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.

This review discusses skin diseases in transgender patients receiving gender-affirming hormone therapy and procedures, highlighting unique conditions and the underdiagnosis that affects their quality of life and mental health.

In this study, androgenetic alopecia was linked to a higher likelihood of hyperlipidemia in both men and women and obesity in women, highlighting it as a potential marker for cardiometabolic risk.